Ivan Kairatov is a distinguished biopharma expert with a deep background in research and development, focusing on the intersection of technology and patient-centric innovation. In this discussion, we explore the implications of the U.S. FDA’s recent acceptance of Gilead’s supplemental New Drug Application for a once-weekly oral version of lenacapavir. We delve into how the findings from the PURPOSE clinical trials support this new formulation and discuss the industry’s move toward flexible, long-acting HIV prevention options that cater to the diverse needs of global populations.
Lenacapavir is currently transitioning from a twice-yearly injection to a potential once-weekly oral formulation; how does this shift impact the overall strategy for HIV prevention?
The shift to a once-weekly 300-mg tablet recognizes that HIV prevention must be adaptable to different lifestyles because a one-size-fits-all approach simply doesn’t work. While the twice-yearly injection is a revolutionary long-acting innovation, an oral option offers a familiar and manageable routine for those who prefer self-administered care over clinical visits. This new formulation aims to broaden the impact of PrEP by offering more choice to those who want or need to protect themselves from HIV. It effectively reduces the barriers to adherence by providing a middle ground between the burden of daily pills and the requirement for semi-annual injections.
The PURPOSE 1 and 2 trials played a crucial role in this submission; what were the most significant outcomes regarding efficacy and the diversity of the participants?
The PURPOSE 1 and 2 trials are significant because they proved high efficacy across an incredibly diverse range of global populations. The research included cisgender women, cisgender men, and gender-diverse individuals, which ensures the data reflects the real-world communities most affected by the virus. When clinical results show such consistent protection across these varied demographics, it builds a necessary foundation of trust for both healthcare providers and patients. This inclusive approach confirms that the 300-mg dose is a robust and reliable option for anyone seeking to reduce their risk of sexually acquired HIV.
Currently, lenacapavir tablets are used as a loading dose or bridge therapy; how would the approval of a standalone weekly oral option change the clinical routine for patients?
Right now, these tablets are a vital safety net used as an initial loading dose or as bridge therapy if a patient’s every-six-month injection is delayed. Transitioning this into a primary, once-weekly regimen would create the first long-acting oral PrEP option available anywhere in the world. This change empowers patients by allowing them to maintain their health through a predictable, weekly routine that they can manage independently. Moving away from clinic-administered injections toward a discreet weekly pill can significantly improve long-term adherence and make prevention feel like a natural part of life.
What is your forecast for HIV prevention?
I forecast a shift toward a modular “toolkit” approach where lenacapavir serves as the foundation for a wide array of future therapies and combinations. We will see the emergence of multiple dosing frequencies, ranging from once-weekly oral tablets to twice-yearly injections, allowing for total personalization of care. This flexibility is essential for addressing individual needs and overcoming challenges like multi-drug-resistant HIV in adults and adolescents. While we still face the reality that there is no cure for HIV or AIDS, these long-acting innovations will move us much closer to ending the epidemic by making prevention as accessible as possible.
